- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: November 2014
- Public Summary Document (PSD) November 2014 PBAC Meeting - PDF
- Public Summary Document (PSD) November 2014 PBAC Meeting - Word
Ofatumumab – November 2014
Ofatumumab; 100 mg/5 mL injection, 5 mL vial, 1 g/50 mL injection, 50 mL vial; Arzerra®
Last updated
6 March 2015